Message from the Chair: The Future of Risk-Based Equipment Qualification

Scientific innovation is accelerating, therapeutic modalities are becoming more complex, and expectations for timely, reliable patient access to medicines continue to rise. In this environment, equipment qualification has evolved to be a strategic capability that directly influences speed to market, supply continuity, and patient safety.

Risk-based equipment qualification, grounded in ASTM E2500 requirements, provides a pragmatic and globally recognized framework for meeting these demands. When applied with discipline, it ensures that engineering effort is directed to systems and functions that protect product quality and, ultimately, patients. ISPE Baseline^® Guides further build on these requirements and provide a rational approach for implementation.

Since its introduction in 2007, ASTM E2500 has reshaped industry thinking by moving away from prescriptive, document-heavy qualification models toward a science- and risk-based approach. The 2024–2025 revision reinforces this evolution, strengthening alignment with life cycle validation, quality by design (QbD), and contemporary regulatory expectations. Its intent is to provide a structured methodology for applying quality risk management (QRM) to facilities, systems, and equipment.

One important element to highlight is that the revised standard treats contamination control strategies (CCS) appropriately as critical inputs into risk assessment and system criticality decisions. CCS that are developed in accordance with Annex 1 and related guidance define what must be protected. ASTM E2500 defines how engineering assurance is applied in a risk-based, life-cycle-oriented manner. In this way, the approach aligns with ICH Q8, Q9, and Q10, as well as ISPE commissioning and qualification (C&Q) guidance, while maintaining clear regulatory boundaries.

At an executive level, the value of risk-based qualification is straightforward: it improves decision-making at an early stage, when decisions matter most. Structured risk assessment during design and specification reduces late-stage surprises that can delay facility startup, disrupt supply, or compromise product integrity. This is especially critical in ATMP manufacturing for therapies often meeting high-priority patient needs, particularly for curative therapies where small batch sizes and high product value leave little tolerance for delay or deviation. Early clarity around system criticality enables organizations to prioritize what truly impacts patient outcomes.

Accordingly, it is also important that execution models must evolve consistent with the risk-based approach. Traditional paper-based commissioning, qualification, and validation (CQV) approaches are increasingly misaligned with the pace and complexity of modern capital programs. Resulting manual workflows and fragmented documentation extend timelines and strain specialized technical resources.

Digital C&Q provides a compelling alternative. By linking risk assessments directly to verification activities, digital execution platforms support real-time test management, automated documentation, and integrated deviation resolution. When aligned with ASTM E2500 principles, digital CQV enables deeper assurance for patient- and product-critical systems while streamlining verification of lower-risk components. The outcome is accelerated facility readiness, stronger data integrity, and enhanced traceability—benefits that directly support faster availability of manufacturing capacity.

Implementation practices have matured in parallel. Integrated C&Q planning embedded within the project life cycle, clearer articulation of system criticality, and deliberate leverage of supplier testing and documentation, enabled by artificial intelligence, reduce duplication without reducing rigor. These practices are particularly relevant as modular facilities, closed processing, and single-use technologies become foundational in ATMP and biologics manufacturing. The ability to deploy flexible capacity quickly is no longer optional; it is essential to meeting patient demand.

Execution discipline remains decisive. Even well-designed qualification strategies can be compromised by unrealistic schedules, scope changes, and resource constraints. Tools such as interdependency matrices provide visibility into how design, automation, utilities, and CQV activities interact. When combined with risk-based qualification, they support informed sequencing, better resource allocation, and protection of critical startup milestones. This reduces the likelihood of delays that ultimately affect patients awaiting therapy.

Notably, regulatory experience also continues to reinforce this direction. Health authorities globally recognize and support science- and risk-based approaches when they are well justified, traceable, and life-cycle-managed. Inspection outcomes increasingly reflect confidence in methodologies that clearly connect risk assessment to verification scope, supported by sound engineering rationale and robust documentation.

Looking ahead, risk-based qualification will continue to evolve alongside greater automation, continuous processing, advanced control systems, and digital twins. Real-time monitoring and sustainability considerations will increasingly inform how equipment fitness is demonstrated and maintained. Across these developments, the objective remains constant: consistent delivery of high-quality therapies to patients who depend on them. This evolution is shaped through shared experience and collaboration across the pharmaceutical engineering community. ISPE provides a neutral forum where practitioners, regulators, suppliers, and academics exchange insights and refine good practices as technologies and expectations advance. Through this collective engagement, risk-based qualification continues to mature in a way that is scientifically sound, operationally practical, and aligned with regulatory intent.

Ultimately, modernizing equipment qualification is an operational enhancement that supports faster access to innovative therapies, more resilient supply chains, and sustained public confidence in pharmaceutical manufacturing. By applying risk-based principles with clarity and discipline, the industry strengthens its ability to deliver safe, effective treatments to patients, consistently and without delay.